The Gastrointestinal Cancer Channel is supported with funding from Gilead Sciences (Silver) and Revolution Medicines (Silver).
VJOncology is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
ASCO 2025 | POLCAGB: chemoradiotherapy in locally advanced gallbladder cancer
Reena Engineer, MD, Tata Memorial Centre, Mumbai, India, discusses interim results from the Phase III POLCAGB trial (NCT02867865), which compared neoadjuvant chemotherapy to chemoradiotherapy in patients with locally advanced gallbladder cancer. Chemoradiotherapy improved overall survival and R0 resection rates compared to chemotherapy alone. Event-free survival was also longer with chemoradiotherapy. Postoperative complication rates were comparable between arms. This interview took place during the 2025 American Society of Clinical Oncology (ASCO) Meeting in Chicago, IL.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
